Last reviewed · How we verify
Alpelisib plus Capecitabine combination
At a glance
| Generic name | Alpelisib plus Capecitabine combination |
|---|---|
| Sponsor | Korean Cancer Study Group |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer (PHASE2)
- SMMART Adaptive Clinical Treatment (ACT) Trial (EARLY_PHASE1)
- Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer (PHASE1)
- Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: